A team of French researchers has now built exactly that tool. Writing in PLOS Computational Biology, Chloé Weckel of the French National Research Institute for Agriculture, Food and the Environment and her colleagues, together with collaborators including Stefan Haar of the École Polytechnique and Romain Yvinec of INRAE, present a generic dynamic model of GPCR signaling that explicitly incorporates receptor trafficking: internalization from the plasma membrane, sorting inside endosomes, and recycling back to the surface. The work, published on September 29, 2026, is not merely another computational exercise. It is an attempt to make the spatial choreography of receptors a first-class citizen in theoretical models, rather than an afterthought, and then to test what that choreography actually contributes to a real hormonal response.

The central premise of the study is deceptively simple. If the kinetics and spatial localization of signaling determine how a cell responds to a ligand, then any model that ignores where the receptor is at a given moment is missing a critical variable. Receptors do not sit still. Ligand binding can trigger their internalization into endosomes, where they may continue to activate G proteins and other effectors, or they may be sorted for destruction. Many receptors are recycled back to the cell surface, replenishing the pool available for the next round of stimulation. Each of these steps has its own timescale, and each timescale feeds back into the shape of the signaling curve, how fast the response rises, how long it persists, and whether it is sustained or transient. The new model captures this interplay directly, allowing researchers to systematically characterize how endosomal dynamics and receptor recycling influence ligand-induced cellular responses.

What makes the approach powerful is its generality. Rather than hard-coding the behavior of one receptor, the authors constructed a framework in which trafficking and signaling compartmentalization are explicit, modular components. This means the same architecture can be adapted to different GPCRs by adjusting parameters, and, crucially, it means the model can be interrogated: which trafficking steps matter most for a given ligand, and under what conditions does endosomal signaling dominate over surface signaling? Such questions have real pharmacological weight. Two drugs that activate the same receptor with similar potency in a standard surface-based assay could produce very different cellular outcomes if one of them preferentially drives internalization or blocks recycling. A model that can distinguish these scenarios offers a far more refined instrument for characterizing ligands than conventional dose-response curves.

To prove the point, the team turned to a receptor with major biological and agricultural significance: the follicle-stimulating hormone receptor, or FSHR. FSH is the master regulator of reproductive function, driving follicle growth in the ovary and sperm production in the testis, and its receptor is a canonical GPCR whose signaling has been studied intensively. The researchers paired their model with high-throughput kinetic data on FSH-induced signaling, using a model selection strategy to determine which combinations of trafficking and signaling assumptions best explained the observed dynamics. This is where the study delivers its most striking surprise: although only a small fraction of FSH receptors is actually internalized, those few endosomal receptors generate a highly active signaling response inside the cell.

The implication of that finding is outsized. If a minority of internalized receptors can punch far above their numerical weight, then any drug or genetic perturbation that alters receptor trafficking, even modestly, could have dramatic consequences for the overall signaling output. A compound that speeds up internalization, slows recycling, or changes how receptors are sorted within endosomes would not merely shuffle receptors around; it would reshape the very profile of the cellular response. For reproductive medicine and livestock breeding, where FSHR ligands are used or studied therapeutically, this reframes how such molecules should be evaluated. A ligand’s pharmacological identity cannot be fully captured without knowing what it does to receptor traffic.

The study also speaks to a broader conceptual shift in cell biology. The emerging view of signaling holds that location is information: a receptor signaling from an endosome encounters a different set of effector molecules, scaffold proteins, and deactivating enzymes than it does at the plasma membrane, so the same receptor can produce qualitatively different downstream effects depending on where it is active. Endosomal signaling has been implicated in sustained responses such as the prolonged activity of certain receptors involved in neuronal function and metabolism. By building trafficking into a quantitative framework, the French team has provided a way to move this discussion from anecdote to arithmetic, converting a qualitative appreciation of spatial organization into testable, parameterized predictions.

Methodologically, the work sits at the intersection of dynamical systems modeling and high-throughput experimental biology. The model selection approach, in which competing mechanistic hypotheses are scored against kinetic data, allows the data themselves to adjudicate which trafficking behaviors are essential and which are dispensable for explaining the observed signaling. This discipline matters because GPCR systems are notoriously over-parameterized: with dozens of rate constants describing binding, internalization, degradation, recycling, and signaling at multiple locations, a model can easily become flexible enough to fit anything. By forcing the model to compete against real FSHR kinetics, the researchers ensured that the retained mechanisms, including the outsized contribution of endosomal signaling, earned their place in the explanation rather than being assumed from the outset.

The authors are careful to frame their contribution as generalizable. Beyond FSHR, the methodology offers a strategy for modeling trafficking dynamics across the GPCR superfamily, which includes receptors for neurotransmitters, hormones, sensory stimuli, and countless other ligands. Because the framework treats internalization, endosomal sorting, and recycling as explicit, tunable processes, it can in principle be calibrated to any receptor for which suitable kinetic data exist. That opens the door to a systematic, comparative pharmacology of trafficking: a future in which every ligand is characterized not only by how strongly it activates a receptor but by how it redistributes that receptor across the cell’s interior landscape.

For drug developers, the message is both a warning and an opportunity. The warning is that assays confined to the cell surface may systematically misjudge compounds whose most important effects occur inside endosomes, or whose toxicity and efficacy hinge on perturbing receptor recycling. The opportunity is that trafficking itself becomes a design target: molecules could be engineered to prolong or curtail endosomal signaling deliberately, tailoring not just the strength of a drug’s effect but its duration and spatial character. As the PLOS Computational Biology study makes clear, the journey of a receptor into the cell is not the end of its story. In many cases, it is where the real signaling begins, and understanding that journey quantitatively may prove as important to future pharmacology as the receptor itself.

Subject of Research: Spatiotemporal computational modeling of GPCR signaling, endosomal dynamics, and receptor recycling

Article Title: Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling

Article References: Weckel, C., Gourdon, J., Darrigade, L., Jugnarain, V., Crépieux, P., Reiter, E., Jean-Alphonse, F., Haar, S., & Yvinec, R. (2026). Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling. PLOS Computational Biology, 22(9), e1014790. https://doi.org/10.1371/journal.pcbi.1014790

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014790

Keywords: GPCR signaling, endosomes, receptor recycling, receptor trafficking, FSHR, computational biology, model selection, pharmacology, cell signaling, ligand characterization, PLOS Computational Biology, spatiotemporal modeling

Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgens, and polycystic ovarian morphology. Because the hypothalamic-pituitary-ovarian axis behaves differently in these patients, with altered gonadotropin secretion patterns and often exaggerated ovarian sensitivity to hormonal cues, reproductive endocrinologists have debated for decades whether a high baseline LH level helps or harms women undergoing controlled ovarian stimulation. Some earlier hypotheses implicated elevated LH in impaired oocyte quality and reduced implantation, prompting some clinics to suppress LH before treatment. Others argued that LH plays a supportive role in theca cell androgen production, which fuels estradiol synthesis in the granulosa cells that nurture developing follicles. Until now, direct clinical evidence in PCOS patients undergoing modern IVF and intracytoplasmic sperm injection protocols has remained thin.

The research team, led by first authors Jun Liu, Xiaoyu Yu, and Fengjuan Zhang, analyzed records from 162 women with PCOS and 120 controls who all underwent IVF or ICSI followed by embryo transfer at a single reproductive medicine center. To probe whether the starting LH level mattered, the investigators stratified the PCOS patients into high-LH and low-LH groups and then systematically compared their endocrine profiles, ovarian stimulation responses, embryological parameters, endometrial characteristics, and pregnancy outcomes. The ethics committee of Sichuan Provincial Women’s and Children’s Hospital approved the protocol, and all participants provided informed consent, with the study conducted under the Declaration of Helsinki.

The baseline comparisons confirmed the expected metabolic and endocrine signature of PCOS: women with the syndrome had higher body mass index, higher testosterone, and markedly elevated anti-Müllerian hormone, the marker that reflects the enlarged pool of small antral follicles that defines the condition. Yet when it came to the mechanics of stimulation, the two PCOS subgroups diverged in an instructive way. Women in the high-LH group displayed a higher antral follicle count, needed lower total gonadotropin doses to drive multifollicular development, and reached higher estradiol concentrations on the day of the hCG trigger. Together these three signals point in one direction: a higher starting LH level was associated with enhanced ovarian responsiveness, meaning the ovaries of these women answered the stimulation drugs more vigorously and more economically.

Crucially, however, that heightened responsiveness did not translate into better reproductive outcomes. Fertilization rates were statistically indistinguishable between the high- and low-LH PCOS groups, as were embryo quality measures and the proportion of high-quality embryos produced per cycle. The stimulation duration itself was similar across groups, indicating that LH status did not accelerate or delay follicular maturation in any clinically meaningful way. When the investigators tracked the downstream pregnancy endpoints, the pattern held firm: biochemical pregnancy rates, clinical pregnancy rates, and live birth rates showed no significant differences attributable to baseline LH. The hormone that visibly reshaped the stimulation cycle left the bottom line untouched.

To place these subgroup findings in a broader context, the authors applied logistic regression modeling to identify independent predictors of clinical pregnancy across the cohort. The result was striking in what it excluded as much as in what it included. Body mass index and anti-Müllerian hormone emerged as significant independent predictors, while baseline LH failed to reach predictive significance. In practical terms, this means a clinician weighing the prognosis for a PCOS patient about to start an IVF cycle would gain more from noting her weight and her AMH level than from her pre-treatment LH value. The study also flagged a sobering signal on the other side of the pregnancy equation: miscarriage risk was elevated in PCOS patients overall compared with controls, and this risk appeared particularly concentrated in the low-LH subgroup, hinting that insufficient LH activity may be associated with a less favorable early pregnancy environment even if it does not impede conception itself.

What might explain the apparent paradox that LH shapes responsiveness without affecting outcomes? The researchers turned to an animal model for mechanistic insight, establishing a PCOS rat model and examining the ovaries for changes in the expression of the two gonadotropin receptors that orchestrate follicular development: the follicle-stimulating hormone receptor, FSHR, and the luteinizing hormone receptor, LHR. In the granulosa cells, the specialized support cells surrounding each oocyte, the PCOS rats showed a coordinated remodeling of receptor expression, with FSHR decreased and LHR increased. This local shift suggests that under PCOS conditions the ovary recalibrates its sensitivity to the two pituitary hormones, potentially compensating for systemic hormonal disturbances in ways that alter how external stimulation protocols are experienced at the cellular level.

The receptor findings carry implications beyond the laboratory. If granulosa cells in PCOS ovaries downregulate FSHR while upregulating LHR, the conventional assumption that FSH-driven stimulation proceeds through the same molecular machinery in PCOS and non-PCOS ovaries becomes questionable. Elevated local LHR expression could partly explain why high-LH PCOS patients respond so exuberantly to exogenous gonadotropins, achieving robust estradiol rises with lower drug doses. At the same time, the dysregulation of this local signaling network may contribute to the disordered folliculogenesis that characterizes the syndrome, and could interact with the elevated miscarriage risk the study documented, though the authors are careful to present the animal data as suggestive of dysregulated gonadotropin signaling rather than proof of a specific causal chain running from receptor expression to pregnancy loss.

For patients, the clinical takeaway is genuinely liberating. Women with PCOS who discover a high LH value on their pre-treatment blood panel need not fear that this number has doomed their cycle, nor should those with low LH assume their chances are compromised at the outset. The study indicates that baseline LH in PCOS is a marker of ovarian responsiveness, useful perhaps for tailoring gonadotropin starting doses and anticipating hyper-response, but not a determinant of fertilization, implantation, clinical pregnancy, or live birth. Meanwhile, the identification of BMI and AMH as independent predictors reinforces what a growing body of literature has argued: weight management and ovarian reserve assessment deserve central places in fertility counseling for PCOS patients. Elevated AMH, though it reflects the abundant follicle pool that makes PCOS ovaries so responsive, emerged alongside BMI as a predictor of clinical pregnancy, underscoring the complex double-edged role this hormone plays in the syndrome.

As with all retrospective single-center studies, the findings come with caveats that invite future work. The cohort of 282 participants is substantial but retrospective design cannot exclude residual confounding, and stimulation protocols, laboratory conditions, and transfer strategies may vary across centers and eras. Nonetheless, the study’s dual design, combining a well-stratified clinical cohort with mechanistic receptor analysis in an animal model, gives it unusual breadth for the field. By demonstrating that the luteinizing hormone value on a pre-treatment lab slip tells a story about ovarian sensitivity but not about babies, the Chengdu team has helped refocus attention on the factors that truly move the needle for women with PCOS pursuing assisted reproduction, while opening a fresh line of inquiry into how the ovary’s own receptor landscape rewires itself in one of the most common hormonal disorders of our time.

Subject of Research: The effect of basal luteinizing hormone levels on IVF/ICSI-ET outcomes in women with polycystic ovary syndrome

Article Title: Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study

Article References: Liu, J., Yu, X., Zhang, F., Liu, W., Zeng, J., & Wang, L. (2026). Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02603-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02603-5

Keywords: polycystic ovary syndrome, luteinizing hormone, IVF, ICSI, embryo transfer, anti-Müllerian hormone, ovarian stimulation, live birth rate, miscarriage risk, granulosa cells, FSHR, LHR